Edition:
United Kingdom

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

49.53USD
21 Sep 2018
Change (% chg)

$0.78 (+1.60%)
Prev Close
$48.75
Open
$48.92
Day's High
$49.83
Day's Low
$48.35
Volume
20,428
Avg. Vol
33,817
52-wk High
$68.91
52-wk Low
$25.58

Select another date:

Thu, Jun 21 2018

Photo

Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

INTERVIEW-Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel, June 21 Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101

* UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGEL™) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC)

Select another date: